Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Efficacy, safety, and pharmacokinetics of eribulin as monotherapy or in combination with irinotecan for patients with pediatric rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, or Ewing sarcoma.

ESMO open·2025

Same author

High-alert medications for hospitalised paediatric patients - a two-step survey among paediatric clinical expert pharmacists in Germany.

Die Pharmazie·2022

Same author

How to build an allogeneic hematopoietic cell transplant unit in 2016: Proposal for a practical framework.

Current research in translational medicine·2017

Same author

Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Same author

Non-anaplastic peripheral T cell lymphoma in children and adolescents-an international review of 143 cases.

Annals of hematology·2016

Same author

Diagnosis and Treatment of Nasopharyngeal Carcinoma in Children and Adolescents - Recommendations of the GPOH-NPC Study Group.

Klinische Padiatrie·2016

Same journal

Sarcoma excision and pattern of complicating sensory neuropathy.

ISRN oncology·2014

Same journal

Idelalisib for the treatment of chronic lymphocytic leukemia.

ISRN oncology·2014

Same journal

Survival prediction score: a simple but age-dependent method predicting prognosis in patients undergoing palliative radiotherapy.

ISRN oncology·2014

Same journal

Palliative Radiotherapy with or without Additional Care by a Multidisciplinary Palliative Care Team: A Retrospective Comparison.

ISRN oncology·2014

Same journal

Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant.

ISRN oncology·2014

Same journal

Clinical features and outcome of sporadic colorectal carcinoma in young patients: a cross-sectional analysis from a developing country.

ISRN oncology·2014

See all related articles

Search research articles

Related Experiment Video

Updated: May 21, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Targeted therapy in Ewing sarcoma.

A Lissat¹, M M Chao, U Kontny

¹Division of Pediatric Hematology and Oncology, Department of Pediatrics, University Medical Center Freiburg, 79106 Freiburg, Germany.

|June 13, 2012

Summary

This summary is machine-generated.

Despite advances in treating nonmetastatic Ewing sarcoma (ES), outcomes for recurrent or metastatic disease remain poor. This review summarizes recent Ewing sarcoma research, focusing on the EWS-ETS fusion and cooperating mutations as potential therapeutic targets.

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Related Experiment Videos

Last Updated: May 21, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Area of Science:

Oncology
Molecular Biology
Genetics

Background:

Nonmetastatic Ewing sarcoma (ES) prognosis has improved, but outcomes for recurrent or metastatic disease are poor.
The EWS-ETS fusion gene is a hallmark of over 95% of ES cases, driving tumor growth.
Understanding ES biology is crucial for developing new therapies.

Purpose of the Study:

To summarize recent research findings in Ewing sarcoma (ES).
To identify and discuss novel therapeutic targets for ES.
To highlight the role of the EWS-ETS fusion protein and cooperating mutations.

Main Methods:

Literature review of recent studies on Ewing sarcoma.
Analysis of the molecular biology and genetic alterations in ES.
Identification of key pathways involved in ES tumorigenesis.

Main Results:

The EWS-ETS chimeric protein drives aberrant transcription, promoting tumor initiation and survival.
Cooperating mutations play a significant role in ES development.
Recent research provides insights into the molecular mechanisms of ES.

Conclusions:

The EWS-ETS fusion and cooperating mutations are critical for ES pathogenesis.
Targeting these molecular alterations holds promise for novel ES therapies.
Further research into ES biology is essential for improving patient outcomes.